Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China

被引：4

作者：

Song, Xiaoting ^{[1
,2
,3
,4
]}

Liu, Bo ^{[1
,2
,3
,4
]}

Luan, Tingting ^{[1
,2
,3
,4
,5
]}

Liao, Shuanglu ^{[1
,2
,3
,4
]}

Tan, Yen ^{[1
,2
,3
,4
]}

Peng, Chengyue ^{[1
,2
,3
,4
,5
]}

Zhao, Zuotao ^{[1
,2
,3
,4
,6
]}

机构：

[1] Peking Univ First Hosp, Dept Dermatol & Venerol, Beijing, Peoples R China

[2] Beijing Key Lab Mol Diag Dermatoses, Beijing, Peoples R China

[3] Natl Clin Res Ctr Skin & Immune Dis, Beijing, Peoples R China

[4] NMPA Key Lab Qual Control & Evaluat Cosmet, Beijing, Peoples R China

[5] Peking Univ, Sch Nursing, Beijing, Peoples R China

[6] Peking Univ First Hosp, Dept Dermatol & Venereol, Xishiku Ave 8, Beijing 100034, Peoples R China

来源：

ALLERGY | 2023年 / 78卷 / 06期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1111/all.15660

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1696 / 1699

页数：4

共 50 条

[31] Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Hamilton, Jennifer D.
Suarez-Farinas, Mayte
Dhingra, Nikhil
Cardinale, Irma
Li, Xuan
Kostic, Ana
Ming, Jeffrey E.
Radin, Allen R.
Krueger, James G.
Graham, Neil
Yancopoulos, George D.
Pirozzi, Gianluca
Guttman-Yassky, Emma
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (06) : 1293 - 1300
[32] Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Ferrucci, Silvia
Casazza, Giovanni
Zussino, Martina
Tavecchio, Simona
Marzano, Angelo V.
Tedeschi, Micol
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
[33] Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
Beck, Lisa A.
Muraro, Antonella
Boguniewicz, Mark
Chen, Zhen
Zahn, Joseph
Marco, Ainara Rodriguez
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (01)
[34] Efficacy of dupilumab in moderate and severe atopic dermatitis
Weidinger, Stephan
Simpson, Eric L.
Silverberg, Jonathan I.
Schmitt, Jochen
Leshem, Yael A.
Katoh, Norito
Chen, Zhen
Zhang, Haixin
Shumel, Brad
Bansal, Ashish
Chao, Jingdong
Lu, Yufang
Rossi, Ana B.
Abramova, Alvina
JEADV CLINICAL PRACTICE, 2023, 2 (02): : 247 - 260
[35] Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1519): : 64 - 66
[36] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Smith, Brandon I.
Engel, Priya
Wu, Jashin
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2299 - 2300
[37] Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to-severe atopic dermatitis treated with dupilumab
Martinez-Cabriales, Sylvia
Marcoux, Danielle
Liy-Wong, Carmen
Prajapati, Vimal H.
Sibbald, Cathryn
Cunningham, Natalie
Lansang, Perla
Tonkin, Rochelle
Joseph, Marissa
Wong, Lauren
Spring, Shanna
Gavigan, Genevieve
Ramien, Michele
PEDIATRIC DERMATOLOGY, 2024, 41 (01) : 5 - 11
[38] Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab
Silverberg, Jonathan, I
Simpson, Eric L.
Thyssen, Jacob P.
Pink, Andrew E.
Weidinger, Stephan
Chan, Gary
Lazariciu, Irina
Clibborn, Claire
Guler, Erman
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[39] LONG-TERM SAFETY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB UP TO 4 YEARS
Blauvelt, A.
Eichenfield, L.
Sierka, D.
Chen, Z.
Khokhar, F.
Marco, A. Rodriguez
Shabbir, A.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S19 - S19
[40] No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab
Andrew Blauvelt
Andreas Wollenberg
Lawrence F. Eichenfield
Haixin Zhang
Debra Sierka
Faisal A. Khokhar
Jignesh Vakil
Arsalan Shabbir
Ainara Rodríguez Marco
Sonya L. Cyr
Advances in Therapy, 2023, 40 : 367 - 380

← 1 2 3 4 5 →